Lidocaine-d6

• Description:

  Lidocaine-d6 (Lignocaine-d6) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

• Product Name Alternative:

  Lignocaine-d6

• UNSPSC:

  12352005

• Target:

  Apoptosis; ERK; Isotope-Labeled Compounds; MEK; NF-κB; Sodium Channel

• Related Pathways:

  Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Others; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Cardiovascular Disease

• Smiles:

  O=C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])CN(CC)CC

• Molecular Formula:

  C14H16D6N2O

• Molecular Weight:

  240.37

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[3]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[4]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1215823-29-2]